Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase.

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Cancer treatment reports

• Publication date

  1979-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 466651
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum.

  1978cited by this paper
• Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol.

  1977cited by this paper
• Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.

  1977cited by this paper
• Bacterial glutaminase in treatment of acute leukaemia.

  1976cited by this paper
• Purification and properties of a highly potent antitumor glutaminase-asparaginase from Pseudomonas 7Z.

  1976cited by this paper
• L-Asparaginase production by the rumen anaerobe Vibrio succinogenes.

  1974cited by this paper
• A simple and rapid method for the estimation of L-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods.

  1974cited by this paper
• Therapeutic properties of a new glutaminase-asparaginase preparation and the influence of the lactate dehydrogenase-elevating virus.

  1974cited by this paper
• Isolation, crystallization, and properties of Achromobacteraceae glutaminase-asparaginase with antitumor activity.

  1972cited by this paper
• L-asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia.

  1967cited by this paper
• Toxic and antineoplastic effects of l‐asparaginase: Study of mice with lymphoma and normal monkeys and report on a child with leukemia

  1966cited by this paper

• Polyethylene Glycol Nanoparticles as Promising Tools for Anticancer Therapeutics

  2019cites this paper
• OVERVIEW ON L-ASPARAGINASE

  2017cites this paper
• Pyridoxal 5 '-phosphate dependent enzymes : classification and catalytic identities

  2017cites this paper
• Desenvolvimento nanotecnológico da L-asparaginase empregando-se metodologia de peguilação

  2017influential citation
• The why and how of amino acid analytics in cancer diagnostics and therapy.

  2017cites this paper
• ADDUCTS AND AN ADDUCT FOR PEG AND GRANULOCYTE-MACROPHAGE COLONY STMULATING FACTOR

  2017cites this paper
• L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL.

  2016cites this paper
• PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.

  2016cites this paper
• Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity- An in silico Approach

  2015cites this paper
• Seeking efficacy in L-asparaginase to combat acute lymphoblastic leukemia (ALL): A review

  2015influential citation
• Efficacy and Toxicity of Asparaginases During Prospective Drug Monitoring in Patients With Childhood Acute Lymphoblastic Leukemia

  2014cites this paper
• Structural and Kinetic Characterization of Guinea Pig l-Asparaginase Type III

  2014cites this paper
• Important Sources and Medicinal Applications of L-Asparaginase

  2014cites this paper
• Pharmaceutical and toxicological properties of engineered nanomaterials for drug delivery.

  2014cites this paper
• Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy

  2013cites this paper
• L-Asparaginase:An Enzyme of Medicinal Value

  2013cites this paper
• L-Asparaginase from Microbes: a Comprehensive Review

  2012cites this paper
• Microbial L-Asparaginase and its future prospects

  2012cites this paper
• Pharmacokinetics, immunogenicity and anticancer efficiency of Aspergillus flavipes L-methioninase.

  2012cites this paper
• Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.

  2011cites this paper
• Role of L-Asparaginase as an Effective Chemotherapeutic agent for Acute Lymphoblastic Leukemia in Children’s

  2011cites this paper
• Recent developments in lipid-based pharmaceutical nanocarriers.

  2011cites this paper
• Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow Relapse: A Children's Oncology Group Study (POG 8866)

  2011cites this paper
• PLP-Dependent Enzymes: a Potent Therapeutic Approach for Cancer and Cardiovascular Diseases

  2011cites this paper
• Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates

  2010cites this paper
• Study on amino amides and enzyme kinetics of L‐asparaginase by MCE

  2010cites this paper
• PEG: a useful technology in anticancer therapy

  2009cites this paper
• PEG conjugates in clinical development or use as anticancer agents: an overview.

  2009cites this paper
• First-line treatment of acute lymphoblastic leukemia with pegasparaginase riccardo

  2009cites this paper
• Anti-cancer PEG-enzymes: 30 years old, but still a current approach.

  2008cites this paper
• Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia.

  2007cites this paper
• Detection of the Antitumor Glutaminase-Asparaginase in the Filamentous Fungi

  2006cites this paper
• Micellar Nanocarriers: Pharmaceutical Perspectives

  2006cites this paper
• L-Asparaginase Review of Pharmacology, Drug Resistance, and Clinical Applications

  2005cites this paper
• Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.

  2004cites this paper
• Poly(ethylene glycol): Protein-repulsive or albumin-compatible?

  2000cites this paper
• Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia

  1998cites this paper
• Stabilization of substances in circulation.

  1998cites this paper
• Novel systems for controlled delivery of macromolecules.

  1996cites this paper
• Biochemical characterization of an L-asparaginase bioconjugate.

  1996cites this paper
• Enzyme-loaded PIBCA nanoparticles (SOD and l-ASNase): Optimization and characterization

  1996cites this paper
• Biochemical Characterization of an L-Asparaginase Bioconjugate

  1996cites this paper
• Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients

  1995cites this paper
• Effect of pegylation on the structure and function of horse cytochrome c.

  1994cites this paper
• Overview of Dana Farber Cancer Institute-Consortium Childhood Acute Lymphoblastic Leukemia Protocols: 1973–1992

  1994cites this paper
• The uses and properties of PEG-linked proteins.

  1992cites this paper
• Points to Consider Response with Clinical Protocol, July 6, 1990

  1990cites this paper
• Immunogenicity of Protein-N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates in A/J and B10 Mice

  1990cites this paper
• Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a Mycoplasma-infected cell line.

  1990cites this paper
• A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma

  1990cites this paper
• Acylation of L-asparaginase with total retention of enzymatic activity.

  1990cites this paper
• Review : Biodegradation of Drug-Modified Polymers in Drug Delivery- A Critical Analysis

  1989cites this paper
• Human immune response to immunotoxins.

  1988cites this paper
• Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits.

  1988cites this paper
• [Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia].

  1988cites this paper
• Alternative delivery systems for peptides and proteins as drugs.

  1988cites this paper
• Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.

  1987cites this paper
• Amino acid requirements of a rat sarcoma as determined by a stem cell assay.

  1987cites this paper
• A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma

  1987cites this paper
• Clinical pharmacology of polyethylene glycol-L-asparaginase.

  1986cites this paper
• Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats, and dogs.

  1986cites this paper
• Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles.

  1986cites this paper
• A nonantigenic covalent streptokinase-polyethylene glycol complex with plasminogen activator function.

  1985cites this paper
• Immune responses to polyethylene glycol modified L-asparaginase in mice.

  1985cites this paper
• [Approaches to improvement of the therapeutic effectiveness of antitumor enzymes (review)].

  1985cites this paper
• Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase.

  1984cites this paper
• Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

  1984cites this paper
• Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia.

  1984cites this paper
• A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and alpha 2-macroglobulin.

  1983cites this paper
• Enzyme-protein conjugates: new possibilities for enzyme therapy.

  1983cites this paper
• Increased antitumor activity of Escherichia coli. L-asparaginase by modification with monomethoxypolyethylene glycol.

  1982cites this paper
• Targeting of drugs: implications in medicine.

  1981cites this paper
• Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids.

  1981cites this paper
• Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.

  1981cites this paper
• Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covalently attached to polyethylene glycol in man.

  1981cites this paper
• Enzyme therapy of cancer, future studies.

  1981cites this paper
• Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.

  1981cites this paper
• Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity.

  1980cites this paper
• Some properties of polyethylene glycol:phenylalanine ammonia-lyase adducts.

  1979cites this paper
• RATIONAL USE OF ANTIMETABOLITES OF SPECIFIC AMINO ACIDS IN COMBINATION CHEMOTHERAPY OF CANCER

  1979cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress First-line Treatment of Acute Lymphoblastic Leukemia with Pegasparaginase

  year unknowncites this paper
• Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations : the impact of expensive chemotherapy

  year unknowncites this paper